With refer to email bearing ref no. L/SURV/ONL/PV/ARJ/ 2024-2025/381 dated March 21, 2025, seeking clarification on significant increase in volume of shares of Eris Lifesciences (the Company), Eris Lifesciences has informed that all the material information / announcement that may have bearing on the operations / performance of the Company which include all the necessary disclosures in accordance with regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and under insider trading regulation, have always been disclosed by the Company within stipulated time and the same is available in public domain. There is no pending information or announcements which have a bearing on the increase in price/volume of security of the Company. Therefore, the increase in volume of security is purely due to market conditions and absolutely market driven and the Company is in no way connected with any such increase in volume.
The above information is a part of company’s filings submitted to BSE.